sb 203580 has been researched along with diosgenin in 2 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (diosgenin) | Trials (diosgenin) | Recent Studies (post-2010) (diosgenin) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 1,095 | 6 | 723 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Beneytout, JL; Bertrand, J; Leger, DY; Liagre, B | 1 |
Beneytout, JL; Bertrand, J; Léger, DY; Lepage, C; Liagre, B; Martin, F | 1 |
2 other study(ies) available for sb 203580 and diosgenin
Article | Year |
---|---|
Diosgenin, a plant steroid, induces apoptosis in COX-2 deficient K562 cells with activation of the p38 MAP kinase signalling and inhibition of NF-kappaB binding.
Topics: Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cyclooxygenase 2; Diosgenin; DNA Fragmentation; Enzyme Activation; Humans; Imidazoles; K562 Cells; MAP Kinase Signaling System; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phytosterols; Poly(ADP-ribose) Polymerases; Pyridines | 2005 |
Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells.
Topics: Apoptosis; Blotting, Western; Cyclooxygenase 2; Diosgenin; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; HT29 Cells; Humans; Imidazoles; MAP Kinase Signaling System; Microscopy, Phase-Contrast; p38 Mitogen-Activated Protein Kinases; Pyridines; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2011 |